On Thursday, June 13th, the United States Supreme Court unanimously rejected a challenge to the abortion pill mifepristone, ensuring its continued availability. The ruling overturned a lower court’s decision to limit access to the drug used in over 60 percent of abortions nationwide, marking a significant win for reproductive rights advocates.
The case, brought by anti-abortion doctors and represented by the conservative Christian legal group Alliance Defending Freedom, argued that the Food and Drug Administration (FDA) had unlawfully relaxed safety regulations for mifepristone. However, Justice Brett Kavanaugh, writing for the court, stated that the plaintiffs lacked legal standing as they had not demonstrated any direct injury. He emphasized that their objections should be addressed through the regulatory or legislative process rather than federal courts.
President Joe Biden welcomed the ruling, underscoring the ongoing fight for reproductive freedom in many states where access to abortion remains severely restricted. “This decision does not change the fact that the right for a woman to get the treatment she needs is imperiled if not impossible in many states,” Biden said. He criticized Republican efforts to ban abortion nationwide, calling their agenda “extreme and dangerous.”
The ruling comes amidst a highly charged political climate, with abortion rights poised to be a central issue in the upcoming presidential election. The conservative-majority Supreme Court had previously overturned the landmark Roe v. Wade decision in 2022, which had guaranteed federal abortion rights since 1973. This reversal led to a wave of state-level abortion bans and restrictions.
Despite the Supreme Court’s 2022 decision, the current ruling maintains the FDA’s authority to regulate medication abortion. This includes measures introduced in 2016 and 2021 that made mifepristone more accessible, such as allowing it to be obtained via mail and extending its use up to 10 weeks of gestation. The court’s decision preserves these regulations, providing stability to the FDA’s drug approval process, which is crucial for patients, healthcare providers, and the pharmaceutical industry.
The plaintiff’s failure to establish standing means that similar challenges could arise in the future. Three states—Idaho, Missouri, and Kansas—have already initiated separate lawsuits with different arguments for standing. Erin Hawley, a lawyer for the plaintiffs, expressed hope that these cases might succeed where this one did not.
Abortion rights supporters, including Nancy Northup, president of the Center for Reproductive Rights, expressed relief at the ruling but frustration over the prolonged legal battle. “Thank goodness the Supreme Court rejected this unwarranted attempt to curtail access to medication abortion,” Northup said, noting that the case should never have advanced this far.
